<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30531303</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7884</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of acquired immune deficiency syndromes (1999)</Title><ISOAbbreviation>J Acquir Immune Defic Syndr</ISOAbbreviation></Journal><ArticleTitle>Brief Report: Malignancies in Adults Living With HIV in Asia.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>307</EndPage><MedlinePgn>301-307</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0000000000001918</ELocationID><Abstract><AbstractText Label="BACKGROUND">Hematological malignancies have continued to be highly prevalent among people living with HIV (PLHIV). This study assessed the occurrence of, risk factors for, and outcomes of hematological and nonhematological malignancies in PLHIV in Asia.</AbstractText><AbstractText Label="METHODS">Incidence of malignancy after cohort enrollment was evaluated. Factors associated with development of hematological and nonhematological malignancy were analyzed using competing risk regression and survival time using Kaplan-Meier.</AbstractText><AbstractText Label="RESULTS">Of 7455 patients, 107 patients (1%) developed a malignancy: 34 (0.5%) hematological [0.08 per 100 person-years (/100PY)] and 73 (1%) nonhematological (0.17/100PY). Of the hematological malignancies, non-Hodgkin lymphoma was predominant (n = 26, 76%): immunoblastic (n = 6, 18%), Burkitt (n = 5, 15%), diffuse large B-cell (n = 5, 15%), and unspecified (n = 10, 30%). Others include central nervous system lymphoma (n = 7, 21%) and myelodysplastic syndrome (n = 1, 3%). Nonhematological malignancies were mostly Kaposi sarcoma (n = 12, 16%) and cervical cancer (n = 10, 14%). Risk factors for hematological malignancy included age &gt;50 vs. &#x2264;30 years [subhazard ratio (SHR) = 6.48, 95% confidence interval (CI): 1.79 to 23.43] and being from a high-income vs. a lower-middle-income country (SHR = 3.97, 95% CI: 1.45 to 10.84). Risk was reduced with CD4 351-500 cells/&#xb5;L (SHR = 0.20, 95% CI: 0.05 to 0.74) and CD4 &gt;500 cells/&#xb5;L (SHR = 0.14, 95% CI: 0.04 to 0.78), compared to CD4 &#x2264;200 cells/&#xb5;L. Similar risk factors were seen for nonhematological malignancy, with prior AIDS diagnosis showing a weak association. Patients diagnosed with a hematological malignancy had shorter survival time compared to patients diagnosed with a nonhematological malignancy.</AbstractText><AbstractText Label="CONCLUSIONS">Nonhematological malignancies were common but non-Hodgkin lymphoma was more predominant in our cohort. PLHIV from high-income countries were more likely to be diagnosed, indicating a potential underdiagnosis of cancer in low-income settings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiamsakul</LastName><ForeName>Awachana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polizzotto</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen-Wei Ku</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanuma</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>Eugenie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Queen Elizabeth Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaiwarith</LastName><ForeName>Romanee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiertiburanakul</LastName><ForeName>Sasisopin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ramathibodi Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avihingasanon</LastName><ForeName>Anchalee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>HIV-NAT, The Thai Red Cross AIDS Research Centre, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunihastuti</LastName><ForeName>Evy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Working Group on AIDS, Cipto Mangunkusumo Hospital, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumarasamy</LastName><ForeName>Nagalingeswaran</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>YRGCARE Medical Centre, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ly</LastName><ForeName>Penh Sun</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>National Center for HIV/AIDS, Dermatology &amp; STDs, University of Health Sciences, Phnom Penh, Cambodia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujari</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ditangco</LastName><ForeName>Rossana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Research Institute for Tropical Medicine, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Cuong Duy</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Bach Mai Hospital, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merati</LastName><ForeName>Tuti Parwati</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Sanglah Hospital, Faculty of Medicine, Udayana University, Bali, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantipong</LastName><ForeName>Pacharee</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fujie</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Nguyen</LastName><ForeName>Kinh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Hospital for Tropical Diseases, Hanoi, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamarulzaman</LastName><ForeName>Adeeba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Malaya Medical Centre, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jun Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sim</LastName><ForeName>Benedict L H</ForeName><Initials>BLH</Initials><AffiliationInfo><Affiliation>Hospital Sungai Buloh, Sungai Buloh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Oon Tek</ForeName><Initials>OT</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Wingwai</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AI069907</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Acquir Immune Defic Syndr</MedlineTA><NlmUniqueID>100892005</NlmUniqueID><ISSNLinking>1525-4135</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N" Type="Geographic">Asia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of interest. All authors stated that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30531303</ArticleId><ArticleId IdType="mid">NIHMS1512081</ArticleId><ArticleId IdType="pmc">PMC6375805</ArticleId><ArticleId IdType="doi">10.1097/QAI.0000000000001918</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS 2014;28(15):2313&#x2013;2318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4260326</ArticleId><ArticleId IdType="pubmed">25111081</ArticleId></ArticleIdList></Reference><Reference><Citation>Rios A HIV-related hematological malignancies: a concise review. Clinical lymphoma, myeloma &amp; leukemia 2014;14 Suppl:S96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">25486964</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobucci RN, Lima PH, de Souza PC, et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. Journal of infection and public health 2015;8(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">25294086</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017;4(11):e495&#x2013;e504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669995</ArticleId><ArticleId IdType="pubmed">28803888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinula L, Moses A, Gopal S. HIV-associated malignancies in sub-Saharan Africa: progress, challenges, and opportunities. Current opinion in HIV and AIDS 2017;12(1):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241291</ArticleId><ArticleId IdType="pubmed">27607593</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengayi M, Spoerri A, Egger M, et al. Record linkage to correct under-ascertainment of cancers in HIV cohorts: The Sinikithemba HIV clinic linkage project. International journal of cancer Journal international du cancer 2016;139(6):1209&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084785</ArticleId><ArticleId IdType="pubmed">27098265</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Chung CY, Wang LH, Lin C, Lin HL, Lin HC. Risk of cancer among HIV-infected patients from a population-based nested case-control study: implications for cancer prevention. BMC cancer 2015;15:133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369071</ArticleId><ArticleId IdType="pubmed">25885746</ArticleId></ArticleIdList></Reference><Reference><Citation>Godbole SV, Nandy K, Gauniyal M, et al. HIV and cancer registry linkage identifies a substantial burden of cancers in persons with HIV in India. Medicine 2016;95(37):e4850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5402588</ArticleId><ArticleId IdType="pubmed">27631245</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaboration of Observational HIVERESG, Bohlius J, Schmidlin K, et al. Incidence and risk factors of HIV-related non-Hodgkin&#x2019;s lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther 2009;14(8):1065&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821596</ArticleId><ArticleId IdType="pubmed">20032536</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohner E, Aids-defining Cancer Project Working Group of IeDea CiE. Non-Hodgkin lymphoma risk in adults living with HIV across five continents: a multicohort study. AIDS 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237186</ArticleId><ArticleId IdType="pubmed">30234606</ArticleId></ArticleIdList></Reference><Reference><Citation>A Decade of Combination Antiretroviral Treatment in Asia: The TREAT Asia HIV Observational Database Cohort. AIDS Res Hum Retroviruses 2016;32(8):772&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4971417</ArticleId><ArticleId IdType="pubmed">27030657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005;38(2):174&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070962</ArticleId><ArticleId IdType="pubmed">15671802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachdeva RK, Sharma A, Wanchu A, Malhotra P, Varma S. Hematological malignancies in human immunodeficiency virus-positive individuals in North India. Leukemia &amp; lymphoma 2011;52(8):1597&#x2013;1600.</Citation><ArticleIdList><ArticleId IdType="pubmed">21657953</ArticleId></ArticleIdList></Reference><Reference><Citation>Gligich O, Chan AC, Mohan D, et al. The Incidence and Risk Factors For Hematological Malignancies and Premalignant Hematological Disorders In HIV. Blood 2013;122(21):4304&#x2013;4304.</Citation></Reference><Reference><Citation>Sankaranarayanan R, Ramadas K, Qiao YL. Managing the changing burden of cancer in Asia. BMC Med 2014;12:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029284</ArticleId><ArticleId IdType="pubmed">24400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. The lancet oncology 2009;10(12):1152&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">19818686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao C, Leyden WA, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS 2012;26(17):2223&#x2013;2231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562666</ArticleId><ArticleId IdType="pubmed">22951631</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiels MS, Islam JY, Rosenberg PS, Hall HI, Jacobson E, Engels EA. Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030. Annals of internal medicine 2018;168(12):866&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6329294</ArticleId><ArticleId IdType="pubmed">29801099</ArticleId></ArticleIdList></Reference><Reference><Citation>Eav S, Schraub S, Dufour P, Taisant D, Ra C, Bunda P. Oncology in Cambodia. Oncology 2012;82(5):269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">22538443</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyomopito R, Lee MP, Phanuphak P, et al. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2010;11(8):519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914850</ArticleId><ArticleId IdType="pubmed">20345881</ArticleId></ArticleIdList></Reference><Reference><Citation>Oladele RO, Bongomin F, Gago S, Denning DW. HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for &#x201c;Prevention Is Better Than Cure&#x201d;? J Fungi (Basel) 2017;3(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753169</ArticleId><ArticleId IdType="pubmed">29371581</ArticleId></ArticleIdList></Reference><Reference><Citation>Achenbach CJ, Buchanan AL, Cole SR, et al. HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis 2014;58(11):1599&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4017888</ArticleId><ArticleId IdType="pubmed">24523217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal E, Gomez JM, Jarrin I, et al. Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment. J Acquir Immune Defic Syndr 2018;78(3):329&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">29543636</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotti D, Raffetti E, Albini L, et al. Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study. PLoS One 2014;9(4):e94768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3997420</ArticleId><ArticleId IdType="pubmed">24760049</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>